Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Curation log — generalized anxiety disorder

Newest entries first. Every content-changing session appends an entry: date, what changed, what was searched, follow-ups for next time. See CLAUDE.md.

---

2026-10-31 — Periodic literature sweep (author: Grok, grok-4.6; independent auditor pending)

Window and method. Publications dated 2026-10-24–2026-10-31 inclusive, plus Entrez-date searches for newly indexed older publications. Read CONVENTIONS.md, CLAUDE.md, SOURCES.md, the prior LOG and INDEX before writing. No publishing or repository commands were run. Exact query strings, counts and returned IDs are preserved in the search manifest.

Sources actually queried. Live PubMed E-utilities esearch/efetch; Europe PMC REST /search (15 topic queries, FIRST_PDATE:[2026-10-24 TO 2026-10-31]) and /fullTextXML for Lee; Crossref /works/{doi} and title search without mailto; ClinicalTrials.gov v2 individual study records and date-filtered studies queries; ISRCTN XML API (PETRA, ToSCA, agomelatine, plus a GAD lastEdited date-range query); WHO ICTRP portal page (JS, not counted as a trial search); ChiCTR search-page attempt; NICE CG113, APA guidelines page, AWMF register and prior PDF route, BAP, CANMAT, WFSBP URL; WHO anxiety fact sheet; ADAA, Mind, NAMI, Anxiety Canada, Anxiety UK, SADAG. Unpaywall skipped (LIFEBANK_CONTACT_EMAIL unset). OpenAlex/DOAJ were not queried.

Limits. Cochrane Library/CENTRAL and SciELO/LILACS could not be searched (HTTP 403 recorded in SOURCES.md; not represented as searched here). Regional-literature absence is not established. WHO ICTRP returned the JS portal, not a date-filtered result set. ChiCTR HTML was compressed/unusable. ISRCTN HTML is a holding page; the documented XML API worked. BAP and CANMAT pages returned bot-challenge HTML; WFSBP guidelines URL returned HTTP error; AWMF PDF route failed this session after working on 2026-10-24. Absences below apply only to the sources and windows stated.

PubMed and Cochrane coverage. Fifteen publication-date topic searches plus a matching "Cochrane Database Syst Rev"[jour] query per topic. All 15 CDSR pdat queries returned 0. A broader CDSR Entrez-date query returned 1 record (Nishiwaki 2026, PMID 42929381, music-based interventions in haemodialysis — not GAD). No new Cochrane review was located; CENTRAL was not searched.

Broad GAD publication-date query: 12 records; broad GAD Entrez-date query: 42; instrument Entrez-date query: 56. Union across dated PubMed topic/Cochrane/edat/instrument/CDSR queries: 79 PMIDs, of which most were GAD-7/anxiety-symptom or non-GAD hits. Europe PMC returned GAD-relevant extras without a PMID: a medRxiv MBSR systematic review (doi:10.64898/2026.10.21.26366048) and a Wellcome Open Research yoga pilot (doi:10.12688/wellcomeopenres.26228.1).

What survived triage. Five journal papers (one with wiki/STATISTICS use), one preprint (bibliography only, with a pooling caveat), a NICE surveillance-status change, and a pipeline update-date. No landmark note, no new open-question ID, no new efficacy recommendation.

Record	Decision and verification depth	Changes
Lee 2026, PMID 42924883	MHACS 2022, analytic n=8,080. Full text opened through Europe PMC (PMC13694471); Tables 2–3 checked. 12-month CIDI/DSM-IV GAD aOR 2.65 (1.56–4.50) for past-12-month suicidal ideation after adjustment including MDE. PubMed listed a mismatched DOI; Crossref title search resolved 10.1177/07067437261500231	Bibliography, red-flags wiki, STATISTICS §6
Elmenawi 2026, PMID 42932137	Administrative GAD after THA; abstract only (no OA full text). Bibliography pointer; no wiki claim	Bibliography only
Karakuş 2026, PMID 42928507	SCID-5 female outpatients, n=60 GAD, disturbed eating 31.7%, BED 13.3%. Abstract only	Bibliography only
Connolly Gibbons 2026, PMID 42925400	GAD-7 monthly recovery curves in naturalistic MBC, not diagnosed GAD. Abstract only; PubMed DOI mismatched, Crossref resolved 10.1007/s10488-026-01532-8	Bibliography only
Niño-Torres 2026, PMID 42957392	GAD-2/GAD-3 vs GAD-7 ≥10 (not vs diagnosis) in 2,402 youth in Bogotá, Buenos Aires and Lima. Abstract only. Reached through PubMed; SciELO/LILACS were not searchable	Bibliography only
Neves 2026, doi:10.64898/2026.10.21.26366048	medRxiv preprint. Full PDF opened. Waitlist GRADE very low; escitalopram comparison is the already-cited Hoge TAME programme (pooled anxiety disorders); several included trials used scale cut-offs. Not used to change wiki synthesis	Bibliography only, labelled preprint
NICE CG113	Live page 2026-10-31: last updated still 15 June 2020; last reviewed 11 September 2026, update needed, work not scheduled	Guideline REGISTRY, guidelines wiki, OPEN-QUESTIONS follow-up
NCT07759128	Updated 2026-10-26; still recruiting, n=576, no results	Clinical-trials pipeline date
ISRCTN16993990	Last updated still 2026-10-21; overall end 2026-10-30 has passed; results fields empty	PETRA row; OPEN-QUESTIONS chase

Retraction and provenance checks. Added journal records have Journal Article (plus Observational Study where listed) publication types and no PubMed retraction/expression-of-concern flag. Matching Crossref records — using the title-resolved DOI where PubMed's DOI was a different paper — have empty updated-by and relation fields. The preprint is Crossref type posted-content / preprint with empty updated-by. This is verification of the new material, not a re-audit of all existing citations.

ClinicalTrials.gov changes. Individually re-fetched all 47 NCT identifiers in condition Markdown. No recruitment-status, enrolment-count or hasResults change versus 2026-10-24. Date-filtered GAD searches: 3 first-posted (mixed microbiota, school wellbeing, preoperative music — none added), 8 last-updated (including NCT07759128 and an electroacupuncture GAD trial still without results), 0 first-results-posted. Commercial open-label CBD (NCT07821840) inspected and not added. NCT-ID PubMed searches for NCT03829241, NCT05749055, NCT05729373, NCT02305797 and the ulotaront/ITI-1284/MM120 phase 3 IDs still returned 0 primary reports.

Guidelines, burden and patient material. NICE surveillance change above is the only guideline-status finding. APA current-guidelines page still has no GAD document. WHO fact sheet still dated 15 September 2026 (470 million / 5.8%, pooled anxiety). ADAA GAD page HTTP 200 (banner for a Lancôme “I’m Fine” women’s-mental-health initiative, not GAD-specific, not added). Mind GAD URL 403, home 200; NAMI 403; Anxiety Canada 200 but a bot-challenge page, so the prior closure notice is not re-verified from readable text this session. No new GAD-specific campaign survived triage.

Dropped. Zhang 2026 eye-movement/EEG n=29; Cotton measurement commentary; Allan suicide review (PubMed DOI resolved on Crossref to a different PTSD paper — not used); Liu adolescent PHQ/GAD-7 comorbidity; prenatal smartphone GAD-7; ashwagandha mixed stress/anxiety RCT; DIALOG+ mixed anxiety/depression protocol; functional-dyspepsia clinic series; yoga tele-pilot preprint n=20; occupational and medical-population GAD-7 surveys. Follow-up full texts still unavailable: Zhang X 2026 (PMID 42868720) not in Europe PMC; Bommersbach 2026 PMC deposit still lacks a body (age range 12–20 remains abstract-only); Brisson 2026 still subscription-only.

Files changed. Three wiki pages, all already draft: red-flags-and-safety-concerns.md, guidelines.md, clinical-trials-landscape.md, last-curated: 2026-10-31. Also bibliography (416 journal PMIDs plus one DOI-only guideline plus one preprint), guideline REGISTRY, STATISTICS, OPEN-QUESTIONS, INDEX, this LOG and the exact-path search manifest. No curated page was edited. No other condition was edited. Independent audit remains pending and must use a different engine.

Next sweep should chase. PETRA results now that the registered overall end (2026-10-30) has passed; distinguish SAP/protocol uploads from actual results. Watch MM120, ITI-1284 and ulotaront efficacy/safety records and ENX-102 publication. Obtain Zhang X 2026, Bommersbach 2026 and Brisson 2026 full texts. Recheck NICE for a start-of-update notice. Retry AWMF PDF, NAMI, Mind GAD page, Anxiety Canada readable closure notice, and ChiCTR. Keep GAD-specific, symptom-selected and pooled-indication findings separate. A GAD-labelled MBSR meta-analysis is on medRxiv; if it is peer-reviewed, re-read the included-trial table before any wiki claim, because the current preprint’s escitalopram comparison is the pooled TAME programme.

---

2026-10-24 — Periodic literature sweep (author: Codex; independent auditor pending)

Window and method. Publications dated 2026-10-17–2026-10-24 inclusive; supplementary Entrez-date searches captured newly indexed older publications. Read CONVENTIONS.md, CLAUDE.md, SOURCES.md, the prior LOG and INDEX before writing. No publishing or repository commands were run. Exact query strings, PubMed translations, returned IDs, per-record registry metadata, retraction checks and triage are preserved in the search manifest.

Sources actually queried. Live PubMed E-utilities esearch/efetch; Europe PMC REST /search (15 topic queries, FIRST_PDATE:[2026-10-17 TO 2026-10-24]) and selected /fullTextXML; Crossref /works/{doi} without mailto; ClinicalTrials.gov v2 individual study records and date-filtered studies queries; ISRCTN's documented XML API (individual PETRA record and a GAD lastEdited date-range query); WHO ICTRP query result page; ChiCTR search attempt; NICE, APA, AWMF and direct AWMF PDF; BAP, WFSBP and CANMAT official pages through web search; WHO anxiety fact sheet and Global Health Estimates update; ADAA, Mind, NAMI, Anxiety Canada, Anxiety UK, SADAG, SESCS and GuíaSalud pages.

Limits. Cochrane Library/CENTRAL and SciELO/LILACS could not be searched (HTTP 403 recorded in SOURCES.md; not represented as searched here). Regional-literature absence is not established. WHO ICTRP returned 21 records for 20 trials, but only the first result page was inspected and no complete update-date sweep was possible. ChiCTR returned HTTP 200 containing an Aliyun bot challenge, not trial results. ISRCTN's HTML page likewise returned a cookie/JS holding page; its documented /api/trial/{id}/format/default and /api/query/format/default endpoints worked after initial incorrect query routes returned 404. Unpaywall skipped because LIFEBANK_CONTACT_EMAIL is unset. OpenAlex/DOAJ were not queried; Embase/Scopus/Web of Science were not searched. Absences below apply only to the sources and windows stated.

PubMed and Cochrane coverage. Fifteen publication-date topic searches covered overview; diagnostic criteria/boundaries; epidemiology/burden; mechanisms; screening/measurement; CBT; other psychological therapies; SSRIs/SNRIs; other drugs; digital delivery; resistant GAD/pipeline; course/relapse; special populations; comorbidity/primary care; guidelines/safety/patient experience. Each had a corresponding dated "Cochrane Database Syst Rev"[jour] query using anxiety/GAD terms plus the topic. All 15 CDSR queries returned 0; a supplementary broader CDSR Entrez-date query also returned 0. No new Cochrane review was located in those PubMed queries; CENTRAL was not searched.

Broad GAD publication-date query: 15 records; broad GAD Entrez-date query: 26; supplementary GAD-7/GAD-2/HAM-A/PSWQ Entrez-date query: 39. Union across the 33 dated PubMed queries: 53 records (52 articles and one updated pharmacogenetic book chapter). Europe PMC returned 28 distinct source/ID keys (13 MED, 14 PMC, one preprint), including duplicates across sources and topics. Three additional MED IDs from Europe PMC were fetched through PubMed E-utilities, bringing the screened PubMed candidate set to 56. No Europe-PMC-only paper survived triage. Full texts of the broad ketamine, group psychedelic-therapy and phenomenological reviews were opened; none supplied a GAD-specific practice-changing synthesis for incorporation.

What survived triage. Two journal papers, two pipeline additions, a PETRA output update and an older guideline omitted from the catalogue. No landmark note, new efficacy recommendation or new open-question ID.

Record	Decision and verification depth	Changes
He 2026, PMID 42889226	Published 2026-10-01, newly indexed 2026-10-17. Full text opened through Europe PMC; Tables 2, 4 and 5 inspected. Retained report-onset medians with their usable-date denominator and pooled-indication limits. Did not convert reporting odds to clinical risk or incidence	Bibliography, safety wiki, STATISTICS §13, OQ-16
Brisson 2026, PMID 42900650	New older-adult Anxious Behaviors Questionnaire. Metadata/abstract only; Europe PMC lists subscription-only full text. Bibliography-level pointer; no numerical wiki claim or diagnostic-accuracy inference	Bibliography only
NCT07786454	Recruiting ulotaront phase 3 open-label safety extension; target 1,120; 26 weeks; completion of a prior GAD phase 3 trial through week 8 required. Updated 2026-10-20, no results	Clinical-trials pipeline; follow-up watch
NCT07123467	Recruiting cannabidiol plus brief CBT target-engagement trial, target 90. Registry calls it phase 3, but primary endpoint is fMRI at approximately five weeks; eligibility permits DSM-5 GAD and/or GAD-7 ≥8. Updated 2026-10-21, no results. Labelled as not diagnosed-GAD-only	Clinical-trials pipeline
ISRCTN16993990	Updated 2026-10-21: SAP v2.0 dated 2026-08-04 and a SAP preprint link uploaded. The preprint metadata was checked in Europe PMC and its DOI resolved through Crossref. These are analysis plans, not results. Final enrolment remains 538, recruitment end 2026-04-02, overall end 2026-10-30; results fields empty	PETRA row; corrected stale follow-up recruitment date in OPEN-QUESTIONS
Spanish NHS / SESCS 2024 national primary-care guideline, doi:10.46995/gpc_641	Historical backfill, not a new October release. Official catalogue, English short-version PDF and companion patient-resource page retrieved; CBT recommendation checked on pp. 7–8. Distinct from the 2020 Málaga adaptation. Crossref resolves the matching monograph. A PubMed DOI search produced an unrelated asphalt paper, rejected after efetch/title/DOI comparison; no PMID was assigned to this guideline	Guideline REGISTRY (#27), guidelines wiki, bibliography, patient-voice source list

Retraction and provenance checks. Both added journal records have only Journal Article publication types and no PubMed retraction/expression-of-concern flag; their matching Crossref records have empty updated-by and relation fields. The German guideline report was also re-fetched from PubMed and checked through Crossref before its catalogue metadata changed. The DOI-only Spanish guideline and PETRA SAP preprint have no Crossref updated-by notice; a PubMed publication-type check is not applicable to a record without a matching PMID. DOI-only identification was verified against title/publisher, not accepted from a loose search hit. This is verification of the new material, not a re-audit of all existing citations.

ClinicalTrials.gov changes. Individually re-fetched all 45 NCT identifiers present in condition Markdown before editing, including five explicitly excluded/out-of-scope records. Compared against the preceding manifest's 43-record snapshot: no recruitment-status, enrolment-count or hasResults change. NCT07767903 was updated 2026-10-20, but remains recruiting at target 384 without results. The two additional IDs documented only in the preceding LOG were also checked; the mixed-diagnosis feasibility record has a newer update date but remains completed without results. Date-filtered GAD searches returned 2 first-posted, 10 last-updated, 0 first-results-posted records. The two first-posted records were a symptom-selected, single-arm university ACT study and a mixed internalizing/basic-science study; neither was added. The updated electroacupuncture study was inspected but not added because no results or material change to treatment synthesis was available. After two pipeline additions, all 47 NCT identifiers now present in condition Markdown have live API provenance; 42 are tracked and five are documented exclusions.

NCT-ID PubMed searches for the four completed programmes still found 0 records: NCT03829241, NCT05749055, NCT05729373, NCT02305797. A broader pipeline-ID search retrieved two general psychedelic reviews, not primary trial reports. Troriluzole and extended-release lorazepam retain posted registry results; absence from PubMed is not absence of results. The PETRA search located its protocol plus unrelated acronym matches, not an efficacy report. Standing all-time absence statements elsewhere were not re-dated by this window-restricted sweep.

Guidelines, burden and patient material. No new GAD guideline survived the dated PubMed/official-body surveillance. NICE CG113 still displays last update 15 June 2020. The direct AWMF PDF resolves the prior access follow-up: title page identifies Version 2.0, revised April 2021, review planned April 2026. Current registry validity or a later replacement could not be established from the JS register page, so the catalogue now states that limit. The WHO anxiety fact sheet remains dated 15 September 2026 with the previously recorded pooled-anxiety figures; the Global Health Estimates news item is dated 2 October, before this window. No new GAD-specific burden estimate was retained. ADAA and Mind condition pages returned 200 today, NAMI 403; Anxiety Canada's closure notice persists. Anxiety UK's /blog route is a submissions page, supplemented with targeted domain searches. No new window-dated GAD campaign or patient-experience source survived triage; the Spanish patient resource is a historical addition, with no new lived-experience theme inferred.

Dropped. Small exploratory TNF-α and structural-imaging studies; maternal-abuse/personality mediation; adaptive GAD-7 score reconstruction; a cannabidiol letter without abstract; mixed depression/anxiety brexpiprazole outcomes; electronic-media-enhanced psychotherapy (full text reviewed, pooled diagnoses, no anxiety benefit); occupational, medical-population and disaster GAD-7 surveys; generic reviews and the insomnia/internalizing preprint. These did not warrant changes to GAD synthesis or evidence-gap claims. Detailed candidate metadata are in the manifest.

Files changed and checks. Three wiki pages: red-flags-and-safety-concerns.md (curated → draft), clinical-trials-landscape.md and guidelines.md (remain draft), all last-curated: 2026-10-24. Also bibliography (411 journal PMIDs plus one DOI-only guideline), guideline REGISTRY (27 documents), STATISTICS, patient-voice sources.md, OPEN-QUESTIONS, INDEX, this LOG and the exact-path search manifest. Changed content pages carry the new frontmatter date. No other condition was edited. JSON, citation-to-source identity, bibliography membership, new body/reference coverage, relative links and actual wiki statuses/counts were checked locally; no publisher/build script was run because it would modify files outside this condition or reach publishing. Independent audit remains pending and must use a different engine.

Next sweep should chase. PETRA after its registered 2026-10-30 end date: distinguish SAP/protocol uploads from actual results. Watch MM120, ITI-1284 and ulotaront efficacy/safety records and ENX-102 publication. Obtain the Zhang substance-use, Bommersbach adolescent and Brisson questionnaire full texts; Bommersbach's PMC deposit still lacks the body, so the prior age-range follow-up remains unresolved. Resolve current AWMF validity/update status, retry NAMI/ADAA news and ChiCTR, and complete WHO ICTRP pagination if regional trial coverage matters. For the pregabalin safety paper, any use of Table 4 should first reconcile adverse-event versus case-report denominators; only onset data were incorporated here. Keep GAD-specific, symptom-selected and pooled-indication findings separate.

---

2026-10-17 — Periodic literature sweep (author: Claude, claude-opus-5-5)

Window. PubMed Entrez date 2026/10/10–2026/10/17 (pdat variants for the broad and Cochrane queries); PMIDs already triaged in literature/sweeps/2026-10-10.json were not re-triaged. Retrieval was live NCBI E-utilities; the PubMed MCP tools were not available. Unpaywall skipped (LIFEBANK_CONTACT_EMAIL unset); Crossref queried without mailto. Query manifest: literature/sweeps/2026-10-17.json.

Sources actually queried. PubMed (20 topic queries plus broad GAD[tiab] 31 edat / 15 pdat hits, "Anxiety Disorders"[majr] 12, GAD-7/HAM-A/PSWQ instrument query 55, CDSR queries, and dated follow-up queries); PMC efetch; Europe PMC REST (FIRST_PDATE:[2026-10-10 TO 2026-10-17], 29 hits, none GAD-relevant without a PMID; 3 preprints, none relevant); ClinicalTrials.gov v2 (all 43 NCT IDs this condition cites, plus GAD studies first posted, updated, or with results posted in the window); ISRCTN API (ISRCTN16993990); Crossref updated-by for every added DOI; NICE CG113, WHO fact sheet, APA guideline page, AWMF register, patient-organisation pages. Not queried / blocked: Cochrane Library/CENTRAL and SciELO/LILACS (HTTP 403 per SOURCES.md); WHO ICTRP (JS portal; ISRCTN queried directly); Embase/Scopus/WoS. Every absence below is an absence in the named databases only.

Cochrane. "Cochrane Database Syst Rev"[jour] × anxiety/anxiolytic/GAD terms in the window: 1 record (medical cannabis for insomnia, PMID 42863850, not GAD); broader psychiatric CDSR query: 3 records, none on GAD. No CDSR review supersedes or contradicts anything this condition asserts.

What survived triage. Three papers and one registry change. No landmark note; no new open question.

Record	Why it survived	Where
Zhang X 2026, PMID 42868720	NESARC-III survival analysis: 10-year GAD incidence after CUD 7.06%, NUD 5.45%, AUD 5.22% vs 1.34% without SUD; stepwise with number of SUDs; remission protective. Adds temporal ordering to Alegría 2010's cross-sectional "half of lifetime GAD" figure	comorbidity-and-primary-care.md, STATISTICS §6d
Bommersbach 2026, PMID 42862569	NSDUH 2024, 15,730 aged 12–20: GAD-7 moderate 9.6%, severe 7.2%; 41.2% (severe) / 48.3% (moderate) untreated. Screening-scale frame, labelled as such	epidemiology-and-burden.md, STATISTICS §2 and §7
Huang 2026, PMID 42858455	China Mental Health Survey (27,505, CIDI 3.0): net of comorbidity, GAD has the largest individual-level self-rated-health decrement of 20 disorders (−14.71 VAS) but not the largest population burden	epidemiology-and-burden.md, STATISTICS §6
ISRCTN16993990 (PETRA)	Record updated 2026-10-14: final enrolment 538 (target 498), recruitment end now 2026-04-02 (page said 2026-03-31), overall end 2026-10-30; no results	clinical-trials-landscape.md

Verification depth, stated plainly. Every figure was checked against the PubMed abstract. For Bommersbach, PMC (PMC13659631) holds only the Key Points and abstract, and every number used appears there verbatim; the body is not yet deposited. Zhang and Huang full texts were not opened (not in PMC or Europe PMC at sweep time). No absence or gap is claimed from any of the three, so FAILURE-MODES rule 5 is not engaged. Bommersbach's abstract gives the age range as 12–20, which is wider than NSDUH's usual 12–17 adolescent band; it is recorded as published, and the full text should confirm it.

Dropped. Murphy 2026 ALSPAC positive childhood experiences (GAD OR 0.91, a secondary subgroup); Woebot postpartum RCT (GAD-7 exploratory, not a GAD sample); Gao 2026 five-element music/lighting (single laboratory session, physiological outcomes); Fonseca 2026 GAD + obesity cross-sectional; Mavi 2026 cognitive-flexibility mediation (PMID 42874673); coping-motives/addictive-behaviour, chromogranin A, Indian ML-prediction and self-guided CBT app pilot (mixed anxiety/depression); occupational and medical-population GAD-7 surveys. The two GAD-tagged ClinicalTrials.gov records first posted in the window (NCT07873905, healthy adults; NCT07876453, mixed depression/panic/GAD feasibility) are not GAD-defined trials and were not added.

ClinicalTrials.gov. All 43 cited NCT IDs resolved. None was updated after 2026-10-10, so there were no status or results changes. No GAD study posted results in October. NCT-ID searches in PubMed for NCT03829241, NCT05749055, NCT05729373, NCT02305797 and the five pipeline records added on 2026-10-10 returned 0, so there is still no journal report.

Guidelines / statistics / patient voice. NICE CG113 still "Last updated 15 June 2020". The APA guideline page still lists no anxiety or GAD guideline ("Anxiety Disorders" there is only patient-site navigation); PubMed returned 0 for an APA GAD guideline and 0 for any anxiety guideline in the window. AWMF 051-028 returned 200, but the page is JS-rendered and no version text could be extracted. The S3 status is therefore unchanged rather than re-verified. WHO fact sheet unchanged (15 September 2026; 470 million in 2023). Anxiety Canada closure notice still present. NAMI 403; ADAA and Mind returned 403 today after 200 on 2026-10-10, which looks like bot-blocking variance rather than a change of content, so organizations.md was not edited.

Retraction checks. PMIDs 42868720, 42862569, 42858455: PubMed publication type "Journal Article" only; Crossref updated-by empty and no relation entries. Titles and DOIs match.

Files changed. wiki/comorbidity-and-primary-care.md (curated → draft), wiki/epidemiology-and-burden.md (draft), wiki/clinical-trials-landscape.md (draft): last-curated set to 2026-10-17 on all three. Also literature/BIBLIOGRAPHY.md (406 → 409), literature/statistics/STATISTICS.md, INDEX.md (counts and statuses), and the new literature/sweeps/2026-10-17.json. OPEN-QUESTIONS.md, guidelines/REGISTRY.md and patient-voice/ were left unchanged because nothing in this window answered, sharpened or opened a question, or changed a guideline. Standing absences in OQ §"Re-run every asserted absence" were not re-dated: this sweep ran window-restricted checks only, which cannot refresh an all-time absence.

Next sweep should chase. PETRA results (trial end 2026-10-30); the ulotaront, ITI-1284 and MM120 pipeline records and their posted results; ENX-102 (NCT05749055) publication; Zhang X 2026 full text, to see whether the cannabis-use-disorder hazard holds after adjustment, and Bommersbach full text, to confirm the 12–20 age range; AWMF S3 version via a non-JS route; ADAA/Mind/NAMI access. Auditor must be a different engine.

---

2026-10-10 — Periodic literature sweep (author: Grok, grok-4.6)

Window. Publications and newly indexed records since 2026-09-02 (prompt date_from; last full-build LOG heading). Identifier retrieval was live NCBI E-utilities (esearch/esummary/efetch) and ClinicalTrials.gov v2 /studies/{NCT}; ISRCTN via isrctn.com/api/query. PubMed MCP tools were not available; E-utilities were the live equivalent. Unpaywall skipped (LIFEBANK_CONTACT_EMAIL unset). Crossref queried without mailto. Query manifest: literature/sweeps/2026-10-10.json.

Sources actually queried. PubMed (topic searches + title-restricted GAD + CDSR-per-topic + dated absence queries; 169 GAD[tiab] edat hits, 11 title-strict GAD hits); Europe PMC REST (FIRST_PDATE:[2026-09-02 TO 2026-10-10], 131 hits, 3 without PMID, 29 preprints); ClinicalTrials.gov v2 (all 36 previously cited NCT IDs plus first-posted/updated/results-posted GAD queries); ISRCTN (ISRCTN16993990); Crossref updated-by for every added DOI; NICE CG113, WHO anxiety fact sheet, APA guidelines page, AWMF, BAP, WFSBP pages; patient-organisation homepages. Not queried / blocked: Cochrane Library/CENTRAL (HTTP 403); SciELO (HTTP 403); LILACS (timeout); WHO ICTRP portal opened but JS-driven so not counted as searched; ChiCTR HTML was compressed/unusable. Absences below are absences in PubMed / Europe PMC / ClinicalTrials.gov / ISRCTN, not universal absences. No regional-literature absence claim is made.

Cochrane. "Cochrane Database Syst Rev"[jour] × GAD/anxiety topic groups in the window: 0 records. No CDSR review superseded or contradicted anything this condition asserts.

What survived triage. Seven papers and a set of registry changes. No landmark note: PETRA is a protocol, Willemsen is measurement, Schmitz's GAD stratum is two trials.

Record	Why it survived
Duffy 2026, PMID 42717383; ISRCTN16993990	PETRA protocol: n=498 UK primary-care add-on pregabalin vs placebo after two antidepressants; GAD-7 at 12 weeks. Sharpens OQ-16/OQ-19
Willemsen 2026, PMID 42809893	Seven GAD scales, 39 symptoms, mean Jaccard 0.21; none of the symptoms in all scales
Mills 2026, PMID 42773855	Secondary analysis of NCT02818751: irritability predicts lower adolescent escitalopram response
Schmitz 2026, PMID 42728340	German DiGA SR/MA; GAD stratum 2 RCTs, pooled SMD −2.31 (CI −5.32 to 0.70) imprecise
Nomoto 2026, PMID 42701687	PRADO: 20.4% of 407 Japanese psychiatric outpatients meet SCID DSM-5 GAD
Cubała 2026, PMID 42848417	DT120/MM120 drug-profile review; Voyage/Panorama still have no posted results
Parsons 2023, PMID 36414206	Protocol for now-completed NCT04895995; NCT-ID search hit

Dropped (honest). Liao 2026 retrospective CCT+paroxetine; EEG/fMRI/cytokine case-control series; Bayrampour speech-prediction (n=19 MDD / 28 GAD); Zainal MIDUS cortisol; González-Spinoglio stepped-care in long-term-care workers (not GAD); PACER ED chest-pain CBT (GAD-7≥8, not diagnosed GAD); inulin GAD-7 college RCT (entrez Apr 2026, outside window); Shipp adolescent IU (2025); Song SC-FC coupling (entrez Jul 2026); commercial CBD and device trials; GAD-alum diabetes false positives.

ClinicalTrials.gov. All previously cited NCT IDs resolved. Status changes: NCT04895995 RECRUITING→COMPLETED (n=30, not 95); NCT07391020 RECRUITING→ACTIVE_NOT_RECRUITING. No new results posted in the window. Unpublished programmes (NCT03829241, NCT05749055, NCT05729373, NCT02305797) still have no PubMed journal report. Added: NCT07807865, NCT07856420, NCT07759128, NCT07767903, NCT07866794. NCT07233278 re-checked and still excluded.

Guidelines / statistics / patient voice. NICE CG113 last updated still 15 June 2020. No APA GAD guideline (PubMed 0; psychiatry.org lists PTSD and eating disorders). WHO fact sheet dated 15 September 2026 now states 470 million / 5.8% for 2023 (was 359 million / 4.4% for 2021); treatment coverage still 27.6%. Anxiety Canada still closed. ADAA and Mind UK now HTTP 200 (were 403). NAMI still 403.

Retraction checks. All 7 added PMIDs: PubMed publication types show neither retraction nor expression of concern; Crossref updated-by empty for each DOI. Title/DOI matched.

Pages edited and demoted to draft: clinical-trials-landscape.md, screening-and-measurement.md, epidemiology-and-burden.md, digital-and-remote-delivery.md, special-populations.md, pregabalin-benzodiazepines-and-others.md, treatment-resistant-gad.md, guidelines.md, patient-experience-and-advocacy.md. Bibliography 399→406. OPEN-QUESTIONS OQ-16, 18, 19, 24, 26, 27, 31, 40 and several dots re-dated. INDEX counts/statuses updated.

Decision noted. PETRA's ISRCTN totalFinalEnrolment field is 0 with recruitment window ending 2026-03-31; that field is not treated as zero actual enrolment. Cubała's mention of "positive Voyage and Panorama topline results" is sponsor-disclosure language in a review and is not written as a trial result.

Next sweep should chase. PETRA results (ISRCTN16993990); ulotaront phase 3s NCT07759128 / NCT07767903 and whether NCT05729373 is ever published; ITI-1284 NCT07807865 / NCT07856420; NCT07866794; MM120 Voyage/Panorama posted results; ENX-102 results after the 2026-09-21 update; any APA GAD guideline; NICE CG113 "last updated"; German S3 successor; a GAD-specific HAM-A MCID; perinatal GAD pharmacotherapy RCT. Recheck NAMI. Auditor must be a different engine.

---

2026-09-02 — Full build (Claude). Awaiting independent audit.

What was built. All 19 planned wiki pages, the complete literature layer, a rewritten OPEN-QUESTIONS.md, and an updated INDEX.md. Every page is status: draft; nothing was promoted. The build engine was Claude — the auditor must be a different engine, per CLAUDE.md.

Artefact	Result
Wiki pages	19 of 19, 126–171 lines each, 24–41 verified citations each (~2,830 lines total)
Distinct verified papers	387, every PMID retrieved live from PubMed E-utilities during this session
Trial registry records	36 NCT IDs retrieved live from the ClinicalTrials.gov v2 API
Non-journal sources	21 organisation/government/WHO pages fetched by HTTP with status codes recorded; 6 further organisations recorded as unverifiable (HTTP 403/timeout)
literature/BIBLIOGRAPHY.md	387 records grouped by section, with tags and cited-by lists
literature/notes/	6 landmark notes (Spitzer 2006, Ruscio 2017, Ruscio 2024, Slee 2019, Kendler 1992, Bschor 2024)
literature/guidelines/REGISTRY.md	26 documents with superseded-by chains, 7 disagreements, 5 structural gaps, 7-item watch list
literature/statistics/STATISTICS.md	~13 topic tables, every figure carrying source/year/population/method, plus 13 stated conflicts
literature/patient-voice/	4 files; 24 organisations catalogued (1 closed, 6 unverifiable); 7 themes each on ≥2 sources; 8 stated coverage limits
OPEN-QUESTIONS.md	40 tiered questions with stable IDs plus an 18-row "dots not yet connected" table

Anchor re-verification. All nine seed anchors were re-fetched live and all nine resolved with matching first author, year and journal. None was discarded. Carpenter 2018 (PMID 29451967) is used only with its pooled scope stated explicitly, as the seed flagged.

Citation integrity. Every PMID in every file was cross-checked programmatically against the session's own fetch store: 387/387 present, 0 fabricated. Every numbered reference line was additionally checked for year and journal match against the retrieved record: 0 mismatches. Roughly a dozen page/volume errors caught by that check were corrected during the build. All markdown tables were checked for column-count consistency: 0 malformed rows.

Searches run (live PubMed E-utilities, 2026-09-02). Approximately 70 distinct queries across: diagnosis and DSM-5/ICD-11 classification; reliability and structured interviews; taxometrics and latent structure; HiTOP/RDoC; network analysis of anxiety–depression symptoms; epidemiology (WMH, NCS-R, NESARC, India NMHS, Bangladesh, Singapore, urban China, Iran); GBD burden; age of onset; treatment gap; twin and molecular genetics; worry models (avoidance, intolerance of uncertainty, metacognitive, emotion dysregulation, contrast avoidance); neuroimaging, HRV, ERP, executive function, inflammation; GAD-7/GAD-2/HADS-A/PSWQ/HAM-A/PHQ-4 psychometrics and cultural bias; USPSTF and WPSI screening; CBT meta-analyses and networks, applied relaxation, low-intensity CBT, delivery formats, mechanisms of change; metacognitive therapy, ACT, MBSR, psychodynamic therapy, emotion regulation therapy, motivational interviewing augmentation; SSRIs/SNRIs (Cochrane, networks, individual trials, dose-response, cost-effectiveness); pregabalin, benzodiazepines, quetiapine, buspirone, agomelatine, silexan, kava, cannabidiol, vortioxetine; internet CBT, apps, conversational agents, adherence; treatment resistance, augmentation, rTMS/cTBS/tDCS; course, remission, relapse prevention, mortality; children/adolescents (CAMS, CAMELS, escitalopram, duloxetine), older adults, perinatal; primary care recognition, collaborative care, guideline concordance, substance-use comorbidity, perceived helpfulness; guidelines (WFSBP, NICE, BAP, German S3, Canadian, CANMAT, Brazilian, AACAP, USPSTF, nutraceuticals); placebo response, trial recruitment, core outcome sets; safety (falls, hyponatraemia, bleeding, discontinuation, paediatric suicidality, benzodiazepine deprescribing, gabapentinoid misuse, thyroid and pheochromocytoma mimics, caffeine); qualitative and lived-experience literature.

ClinicalTrials.gov queries (v2 API, 2026-09-02). Recruiting GAD studies; completed phase 2/3 GAD studies sorted by start date; targeted queries for MM120, ITI-1284, ABBV-932 and psilocybin; and individual record lookups to verify the five NCT IDs cited from published trials (NCT03522844, NCT00426426, NCT02818751, NCT03924323, NCT00052078 — all confirmed COMPLETED with matching enrolment). A search-hygiene note for future sweeps: "GAD" also abbreviates glutamic acid decarboxylase, so naive registry queries return type 1 diabetes GAD-alum immunotherapy trials (e.g. NCT01785108, NCT05351879). These were excluded explicitly and the caveat is written into clinical-trials-landscape.md.

Scoping decisions taken during the build.

1. Pooling is labelled at the point of use, not once. Every effect size taken from a source that pools anxiety disorders (Carpenter 2018, Hofmann 2008, Bandelow 2015, Pauley 2023, Hoge 2023, Jakubovski 2019, Seppala 2018, Henssler 2024, Kalfas 2025, Haller 2021, Hyde 2022, Black 2019, Wagner 2026's non-GAD strata) carries an inline "pooled" marker. GBD figures are flagged as anxiety-disorder figures because GBD does not model GAD.
2. Comorbid depression is cross-linked, never absorbed. The GAD–MDD genetic correlation and the pure-vs-comorbid dispute are treated as content on the-diagnostic-boundary.md and comorbidity-and-primary-care.md, with depression curated elsewhere.
3. PTSD is cross-linked as a neighbour from diagnosis-and-classification.md, epidemiology-and-burden.md, patient-voice/README.md and overview.md; nothing about PTSD is restated here.
4. Four different prevalence frames are separated explicitly — interview-diagnosed GAD, ICD-11 algorithm self-report, administrative claims, and screening-scale symptoms — because conflating them is the commonest error in secondary reporting of GAD statistics.
5. Conflicting syntheses are presented as conflicts, not averaged. Digital vs face-to-face CBT; benzodiazepine tolerability within-class vs across-class; quetiapine augmentation; clinic vs community prognosis; responder vs continuous analyses; drug vs psychotherapy effect sizes across different control types.

Things that could not be verified, carried as [unverified]. GAD-specific κ from the DSM-5 field trials (Regier 2013 reports only the distribution across 15 adult diagnoses); pregabalin's US regulatory status for GAD; agomelatine hepatic-monitoring requirements; a GAD-specific HAM-A MCID; a systematic audit of GAD trial reporting; DIF studies of the GAD-7 outside one US undergraduate sample; treatment-response data for criteria-excluded (non-excessive, <6-month, 2-symptom) cases; a German S3 revision later than 2013/2014; the 2002 WFSBP first edition (referenced by its 2008 successor but not separately retrieved); published results for four completed GAD phase 2/3 programmes (troriluzole NCT03829241, ENX-102 NCT05749055, SEP-363856 NCT05729373, extended-release lorazepam NCT02305797). Each is flagged in place and dated.

Positively-stated absences, re-searched and dated 2026-09-02. No current APA practice guideline for GAD (the 1998 anxiety guideline covers panic disorder, PMID 9585731). No GAD-specific GBD estimate. No screening trial showing outcome benefit. No comorbidity-stratified treatment estimate. No fixed-versus-indefinite continuation trial. No dismantling trial of collaborative care. No preference-based drug-versus-therapy design in GAD. No adult GAD core outcome set (one is in development for paediatric anxiety, PMID 37244653). No GAD-specific patient priority-setting partnership. Only one located qualitative study of people diagnosed with GAD (Hurtado 2020, PMID 31908140).

Notable findings that reshaped the build. (i) GAD's placebo pre-post effect is d_av 1.23, second of nine psychiatric disorders (Bschor 2024, PMID 38809560) — this became the organising fact of clinical-trials-landscape.md and is cross-referenced from every treatment page. (ii) GAD carries 48% excess all-cause and 55% excess natural-cause mortality (Wagner 2026, PMID 42136520), which moved mortality from a footnote to a section. (iii) 70% of treated patients find treatment helpful but only ~30% would persist through enough encounters to reach the modelled ceiling (Stein 2021, PMID 34372811) — this reframes the treatment gap as partly a persistence problem. (iv) A commissioned UK RCT of drug versus therapy was terminated because three-quarters of eligible patients refused randomisation to medication (Kalpakidou 2019, PMID 31126337), which makes the central comparative-effectiveness question possibly unanswerable by randomisation. (v) Four independent literatures converge on uncontrollability rather than excessiveness as GAD's discriminating feature, and no revision proposal has been built on that convergence (new OQ-36). (vi) Anxiety Canada's website now carries a closure notice — a national patient organisation has ceased operations.

Follow-ups for the auditor.

1. Re-fetch all 387 records and re-check every claim→PMID pair; the reference lines were machine-checked for year and journal but not for whether the claim matches the abstract.
2. Re-run the searches behind every asserted absence listed above and re-date them; stale absences are the commonest real error.
3. Resolve [unverified] flags where possible — in particular the DSM-5 field-trial GAD κ (needs full text), pregabalin's regulatory status, and whether a German S3 revision exists outside PubMed.
4. Check the four numbers most likely to be mis-transcribed: Cardoner 2025's 12-week HAM-A MD (reported as +0.99 where every other timepoint is negative — recorded as published, unreconciled); Stein 2021's agomelatine HAM-A difference of 6.30, roughly double the reference network's best estimate; Gundugurti 2024's cannabidiol GAD-7 difference of −7.02 with an implausibly narrow interval for n=178; and Duan 2025's rTMS response OR of 291.40 (95% CI 13.08–6490.21).
5. Verify the perinatal GAD-7 cut-off claim (13 rather than 10) against Simpson 2014 full text before any clinical use is implied.
6. Re-verify the patient-voice organisation directory: URLs decay, and one organisation in it has already closed. Attempt the six unverifiable sites again with a different approach.
7. Promote to curated only pages where every citation resolves and matches with no unresolved substantive issue. Record both engines by name in the audit entry.

---

2026-09-02 — Seeded (Claude)

Created the scaffold: INDEX.md with a 19-page plan (16 topical + 3 standing house pages) and a 9-record anchor table, a seed OPEN-QUESTIONS.md, this log, and the empty wiki/ and literature/ layers. No wiki pages written.

Searches run (live PubMed E-utilities, 2026-09-02). Scoping: generalized anxiety disorder 17,415; anxiety disorders[MeSH Major Topic] 69,338. Per-page topic counts in INDEX.md, including epidemiology 6,253, comorbid depression 2,809, GAD-7 2,202, CBT 1,640, course/relapse/remission 1,609, worry/intolerance of uncertainty 1,501, digital delivery 1,132, children and older adults 915, treatment-resistant 291, SSRI/SNRI 175, primary-care detection 125, pregabalin/benzodiazepine 67.

Query-hygiene note. Five initial queries were over-specified and returned single- or double-digit counts that would have wrongly suggested empty pages (neurobiology worry returned 9; long-term course relapse returned 18; digital internet-delivered therapy returned 20). Re-run with proper alternation they return 1,501, 1,609 and 1,132. Affected counts are marked † in INDEX.md. This is the mirror of the PTSD problem in the same session: loose Booleans inflate, over-specified ANDs deflate, and both distort a page plan.

Anchor records resolved live: 9, listed in INDEX.md.

Scoping decisions. The gap between 17,415 GAD records and 69,338 anxiety-disorder records is the scoping problem: most apparent GAD literature is anxiety-disorder literature or GAD-with-depression literature. Three borders written into INDEX.md — the condition owns GAD and not panic, social anxiety, phobias or OCD; comorbid depression is cross-linked to depression rather than absorbed; PTSD is a neighbour, seeded in the same session, and cross-links. Where a trial or guideline pools anxiety disorders, the page must say so explicitly, because a pooled anxiety effect size is not a GAD effect size. One anchor is flagged in the table for exactly this reason: Carpenter 2018 (PMID 29451967) covers anxiety and related disorders, so any GAD-specific figure must come from its GAD stratum or a GAD-specific source.

The diagnostic boundary is scoped as content. Whether excessive worry should remain a required criterion is a live published dispute — the same group that produced the cross-national epidemiology has argued for removing it (PMID 28297020; PMID 39364896). It gets a dedicated page and is left unresolved with both sides sourced.

Flagged for the build pass. No anchor yet for NICE/APA/WFSBP guidelines, metacognitive therapy, internet-delivered CBT trials, maintenance and relapse-prevention trials, perinatal and paediatric GAD, or patient-organisation material.

Follow-ups. Build with tools/build-condition.sh generalized-anxiety-disorder; auditor must differ from the writer.

---

2026-09-02 — independent audit

Authorship and independence. Original pages and literature layer: Claude. Independent auditor and corrective editor: Codex. Codex did not participate in the original authorship.

Coverage checked. Audited all 19 wiki pages and every artifact in literature/, plus INDEX.md and OPEN-QUESTIONS.md. Re-fetched 387 original distinct PMIDs by live PubMed E-utilities calls, then live-fetched 12 additional PMIDs discovered during correction; the final corpus contains 399 distinct PMIDs, all resolving to the claimed record. Re-fetched all 38 distinct NCT IDs individually from the live ClinicalTrials.gov v2 API. Checked 2,003 original claim–citation occurrences across narrative artifacts, including 1,193 inline PMID occurrences in wiki prose, and rechecked that every wiki-body PMID appears in that page's reference list. Checked 27 external URLs live: 20 returned HTTP 200, six returned bot/Cloudflare 403 responses, and one failed to connect; the inaccessible entries remain explicitly labelled rather than treated as verified content.

Errors found and fixed. The corrections below are exhaustive for this audit pass.

Area	Error in Claude-authored material	Correction made
German guideline	The 2014 S3 document was labelled current and a later revision “not located.”	Added the first revision (Bandelow 2022, PMID 34609587), which reviewed 92 additional RCTs; updated the registry, synthesis, bibliography and watch list.
Treatment resistance	Repeated claims said no consensus definition or staging model existed.	Added the 36-expert Delphi consensus with 14 recommendations and a potential trans-anxiety staging model (Domschke 2024, PMID 38214637); retained the narrower gap that GAD-specific validation and adoption remain limited.
Qualitative evidence	The patient layer repeatedly claimed exactly one GAD-specific qualitative study.	A fresh PubMed search located several. Added GAD-specific work on primary-care implementation, perinatal behaviours, motivational-interviewing experience and dietary-trial participation (PMIDs: 33218311, 35716017, 21644188, 41587136), while retaining the evidence-base limitation.
Patient preference	The corpus claimed no preference-based GAD comparison existed.	Added the quasi-experimental patient-choice comparison of e-CBT, medication and combination (Stephenson 2023, PMID 38125282); reframed the gap as lack of a design supporting causal comparative inference.
GAD-7 invariance	Sex-based measurement invariance was described as unstudied.	Added partial strong sex/time/language invariance in young adults (PMID 39880312, already present) and a 165,872-patient sex-invariance study (Saunders 2023, PMID 37118684); narrowed the remaining gap to cross-cultural and diagnosed-GAD generalisability.
Core outcomes	The corpus said adult GAD had no core-outcome work.	Added the patient-engagement study developing candidate perinatal-GAD outcomes (Stallwood 2026, PMID 42003419); retained the dated absence of a general-adult GAD core set.
Perinatal trials	A 2020 review's “no treatment trials” finding was repeated as a current universal absence.	A fresh search found a 2024 secondary analysis of a systems-level cluster RCT measuring perinatal GAD symptoms (Zimmermann 2024, PMID 38992743). The remaining dated gap is specifically perinatal GAD pharmacotherapy RCTs.
Fear generalisation	Lissek's n=22 signal was described as never replicated.	Added the later 28-GAD/30-control study that found no difference on most indices (Tinoco-González 2015, PMID 26459843); the evidence is now described as small and conflicting.
Hydroxyzine	Hydroxyzine was left wholly unverified.	Added the 334-participant, three-month double-blind trial: HAM-A change −12.16 versus −9.64 with placebo, p=0.019, with response and remission also favouring hydroxyzine (Llorca 2002, PMID 12444816).
Kava	An impossible source value was repeated as a GAD null: MD −0.17 with 95% CrI −2.55 to −1.97.	Explicitly identified the PubMed abstract's internal inconsistency and removed the directional GAD conclusion pending a corrected source value.
Trial scope	NCT07233278 was presented as a GAD rTMS pipeline trial.	Live record showed recurrent pregnancy loss with anxiety, not a GAD-defined sample; removed it from the active GAD table and documented its exclusion.
Trial population	NCT04895995 was presented as a general GAD digital-CBT programme.	Qualified it as a cardiovascular-disease population selected for generalized-anxiety symptoms, not diagnosed-GAD-only.
Trial reporting	Four completed programmes were labelled unpublished without distinguishing registry results.	NCT-ID PubMed searches found no journal articles; ClinicalTrials.gov has posted results for NCT03829241 and NCT02305797. The pages now distinguish registry results from journal publication.
Regulatory claims	Pregabalin licensing, agomelatine monitoring and “quetiapine off-label everywhere” were asserted without retrieved regulatory sources.	Removed jurisdiction-wide assertions; efficacy and safety statements now remain within the verified literature, and regulatory status is described as jurisdiction-dependent or outside scope.
Mortality	Similar natural-cause and all-cause RRs were used to infer that excess deaths were dominated by physical illness.	Removed the unsupported decomposition; overlapping outcome categories and intervals cannot establish causal composition.
Cross-treatment rankings	Collaborative-care NNTs, drug mean differences, psychotherapy SMDs and rTMS effects were repeatedly compared as if exchangeable.	Removed “best intervention,” “three times more effective” and similar rankings; retained effects with their own population, comparator and endpoint.
Causal language	Placebo response was said to explain trial failures; statistical mediation was called causal; persistent thyroid symptoms and later depressive symptoms were treated as diagnostic proof.	Reframed each as context, association or differential-diagnosis evidence; removed unsupported causal certainty.
Paediatric follow-up	“Treatment type does not matter” and modality interchangeability were inferred from remission analyses.	Added that treatment assignment predicted some functional trajectories and reframed the question around joint remission and functional outcomes.
Medical safety	A source on SSRI-associated bleeding was presented as evidence for an SSRI–NSAID/antiplatelet interaction; age 40–50 and universal thyroid-testing implications were added without support.	Restricted the bleeding claim to SSRI exposure, removed the unsupported age threshold, and changed testing language to feature-guided differential assessment.
Diagnostic reliability	The unavailable GAD-specific DSM-5 field-trial kappa was left as a bare unresolved marker.	Stated positively that the PubMed abstract reports only the cross-diagnosis distribution and that no GAD-specific value is inferred.
Evidence gaps	Bare [unverified] markers covered HAM-A MCID, fixed-versus-indefinite continuation, collaborative-care dismantling, older-adult escitalopram replication, CBT by depressive comorbidity, criteria-excluded treatment response, medical-work-up yield and digital equity.	Re-ran targeted PubMed searches and converted each into a positively stated, dated evidence-gap sentence. The MM120 2.5-point HAM-A threshold is correctly labelled a prespecified assumption rather than an anchor-based MCID validation.
Attribution and references	Compound surnames and several body citations/reference lists were inconsistent; three body PMIDs were missing from page references.	Normalised van Dis, Ter Kuile, Di Nardo, Trenoska Basile, Af Winklerfelt Hammarberg and Ishrat Husain; added missing page references for PMIDs 40130828, 40906494 and 19351943; final body/reference coverage check found zero omissions.
Landmark-note rhetoric	Notes described one review as the first at scale, placebo as explaining failures, and GAD-7 as the route by which most people are identified.	Removed unverifiable priority and prevalence claims and narrowed interpretation to what the cited studies establish.

Remaining flags and limitations. No bare [unverified] marker remains in current wiki or literature prose. The kava credible interval remains an explicitly documented error in the source abstract, not a repaired number. The GAD-specific DSM-5 field-trial kappa remains unavailable from the PubMed abstract and is not asserted. Six organisation pages returned access-control responses and one failed to connect during the live HTTP pass; their access status remains recorded. Dated negative searches are evidence gaps, not proof of universal absence, and should be rerun at the next curation date.

Promotion result. All 19 of 19 wiki pages now have status: curated. Every current PMID and NCT ID resolved live, every wiki-body PMID is represented in its page references, all relative links resolve, and no unresolved substantive citation mismatch remains. CONDITIONS-ROADMAP.md was intentionally not modified.

2026-10-08 — correction of dot row D15, which misstated its own evidence (Claude Opus 5, author)

Why. The novelty gate returned narrowed unanimously on D15. The row claimed "four independent literatures converge on uncontrollability of worry" and that "no proposal has been built on the convergence". Neither holds, and the second is contradicted by a paper the row itself cites.

What was wrong. Of the four cited literatures, only Hallion 2013 (PMID 23713499) directly supports uncontrollability's incremental validity. Faravelli 2012 found muscle tension, not uncontrollability, distinguished GAD (PMID 22578985) — a material mismatch, since the row used it as specificity evidence. Cai 2024 shows uncontrollable worry is central and not a bridge symptom in pooled depression–anxiety networks (PMID 38238548), which is centrality, not diagnostic specificity. Sun 2017 is a meta-analysis of metacognitive beliefs about the uncontrollability and danger of thoughts (PMID 28763680), a different construct from the DSM symptom. On the other side, Ruscio 2024 (PMID 39364896) already proposes exactly two of the three things the row said nobody had proposed — drop excessiveness, retain uncontrollability — in 133,614 adults across 28 WHO World Mental Health surveys, raising lifetime prevalence from 2.6% to 4.0%. And Andrews 2010 (PMID 20058241) retains excessive worry in its "generalized worry disorder", so the claim that every revision proposal targets excessiveness is also wrong.

What the row now says. Two of the three elements are published. The residual is the third alone: whether reweighting the six associated symptoms by discriminative value improves held-out specificity over both DSM-5 and Ruscio's unweighted excessiveness-free rule.

Provenance of this pass. Every PMID written into the row was re-fetched live from PubMed in this session (E-utilities via the bio-research PubMed tool), its publication types inspected for Retracted Publication / Expression of Concern, and its DOI checked against Crossref's updated-by field. Twenty records were checked across the three conditions corrected today; none carried a retraction, withdrawal or expression of concern. No identifier was carried over from the gate verdict files on trust: those were written in an earlier session, and SOURCES.md's prime rule binds the session that writes the claim.

Author: Claude Opus 5. Auditor: pending — must be a different engine.

2026-10-08 — independent audit of Claude Opus 5's D15 correction (Codex, auditor)

Live records re-fetched. PubMed E-utilities: row PMIDs 23713499, 22578985, 38238548, 28763680, 39364896, 20058241; search candidates 21227450, 12405483, 21284071, 31361153, 17371130, 42082212, 27485325. All six row records exist and match the papers. Their PubMed publication types and their actual PubMed-listed DOI's Crossref updated-by fields show no retraction or expression of concern.

Searches re-run, live PubMed ESearch, 2026-10-08 (exact terms; counts are database hits, not eligible studies).

Query	Count
("generalized anxiety disorder" OR "generalised anxiety disorder") AND (excessiveness OR "excessive worry") AND (uncontrollability OR "uncontrollable worry") AND ("muscle tension" OR "associated symptoms") AND (criteria OR diagnostic)	1
("generalized anxiety disorder" OR "generalised anxiety disorder") AND ("symptom weighting" OR "weighted symptoms" OR "weighted criteria" OR "diagnostic efficiency" OR "symptom discrimination") AND (DSM OR diagnosis OR criteria)	6
("generalized anxiety disorder" OR "generalised anxiety disorder") AND "Cochrane Database Syst Rev"[jour] AND (criteria OR diagnostic OR classification) AND (excessiveness OR uncontrollability OR "muscle tension")	0
("generalized anxiety disorder" OR "generalised anxiety disorder") AND (excessiveness OR "excessive worry") AND (uncontrollability OR "uncontrollable worry") AND ("weighted symptoms" OR "symptom weighting" OR "weighted criteria")	0
"generalized anxiety disorder"[tiab] AND ("differential symptom weighting"[tiab] OR "symptom prioritization"[tiab] OR "symptom weights"[tiab])	0
"generalized anxiety disorder"[tiab] AND "excessiveness"[tiab] AND "associated symptoms"[tiab]	1

Corrections. Confirmed Ruscio's 133,614 adults in 12 lower/middle-income plus 16 high-income surveys (28 total), and the 2.6% to 4.0% lifetime-prevalence change when excessiveness is removed while other DSM-5 criteria remain. Confirmed Andrews's proposed disorder retains excessive worry. Hallion's incremental-validity sample comprised 126 adults already diagnosed with GAD, so it is not a direct diagnostic-specificity test against non-GAD; corrected that implication. Faravelli found muscle tension was the only tested symptom distinguishing GAD from non-GAD, but did not test uncontrollability, so removed the false head-to-head framing. Cai identifies uncontrollable worry among the most central symptoms, not among the most frequent bridges; it does not establish that the symptom is never a bridge. Sun's metacognitive-belief construct is separate from the DSM symptom. Narrowed the residual to a dated PubMed failure to locate a combined adult reweighted rule tested on held-out diagnostic discrimination and impairment prediction, rather than claiming universal absence.